v3.26.1
Revenue (Tables)
 3 Months Ended
Jul. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Net Sales by Segment and Division and by Market Geography
The table below illustrates net sales by segment and division and by market geography for the three months ended July 31, 2026 and July 25, 2025. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.
Worldwide
Three months ended
(in millions)July 31, 2026July 25, 2025
Electrophysiology Therapies$2,218 $1,712 
Interventional Cardiology Therapies894 834 
CardioVascular Surgery477 436 
Peripheral Vascular Health338 302 
Cardiovascular 3,927 3,285 
Cranial & Spinal Technologies1,365 1,211 
Specialty Therapies774 702 
Neuromodulation539 514 
Neuroscience 2,678 2,427 
Surgical & Endoscopy1,740 1,601 
Acute Care & Monitoring539 471 
Medical Surgical 2,279 2,073 
Reportable segment net sales8,884 7,785 
Diabetes843 721 
Other operating segment(1)
29 33 
Other adjustments(2)
— 39 
Total net sales$9,756 $8,578 
U.S.
International
Three months ended
(in millions)July 31, 2026July 25, 2025July 31, 2026July 25, 2025
Cardiovascular$1,853 $1,479 $2,074 $1,806 
Neuroscience1,813 1,624 864 803 
Medical Surgical982 884 1,297 1,188 
Reportable segment net sales4,649 3,988 4,236 3,797 
Diabetes240 217 603 504 
Other operating segment(1)
17 20 12 14 
Other adjustments(2)
— — — 39 
Total net sales$4,906 $4,224 $4,850 $4,354 
(1)Includes operations and ongoing transition agreements from businesses the Company has exited or divested.
(2)Reflects adjustments to the Company's Italian payback accruals as further described below.